STAAR Surgical Company (NASDAQ:STAA) has earned a consensus broker rating score of 2.00 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company. STAAR Surgical’s rating score has improved by 20% in the last three months as a result of various analysts’ ratings changes.
Brokers have set a 12-month consensus price objective of $17.67 for the company and are predicting that the company will post $0.03 EPS for the current quarter, according to Zacks. Zacks has also given STAAR Surgical an industry rank of 116 out of 265 based on the ratings given to related companies.
Several equities research analysts have weighed in on STAA shares. Benchmark Co. reiterated a “buy” rating and issued a $21.00 target price on shares of STAAR Surgical in a report on Monday, November 20th. Canaccord Genuity increased their target price on shares of STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 17th. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. BidaskClub upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Finally, TheStreet upgraded shares of STAAR Surgical from a “d+” rating to a “c” rating in a report on Tuesday, August 15th.
Several large investors have recently modified their holdings of STAA. Goldman Sachs Group Inc. acquired a new stake in STAAR Surgical in the 1st quarter valued at $111,000. Virtu KCG Holdings LLC acquired a new stake in STAAR Surgical in the 2nd quarter valued at $118,000. Stephens Inc. AR increased its stake in STAAR Surgical by 2.6% in the 2nd quarter. Stephens Inc. AR now owns 12,238 shares of the medical instruments supplier’s stock valued at $132,000 after buying an additional 315 shares during the last quarter. Prudential Financial Inc. acquired a new stake in STAAR Surgical in the 3rd quarter valued at $138,000. Finally, Citadel Advisors LLC acquired a new stake in STAAR Surgical in the 3rd quarter valued at $172,000. Institutional investors and hedge funds own 77.47% of the company’s stock.
STAAR Surgical (NASDAQ:STAA) traded up $0.40 on Monday, hitting $16.65. 184,811 shares of the stock traded hands, compared to its average volume of 90,848. STAAR Surgical has a twelve month low of $8.95 and a twelve month high of $16.75. The company has a current ratio of 2.24, a quick ratio of 1.72 and a debt-to-equity ratio of 0.02.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect STAAR Surgical Company (STAA) to Announce $0.03 Earnings Per Share” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://stocknewstimes.com/2017/12/06/analysts-expect-staar-surgical-company-staa-to-announce-0-03-earnings-per-share.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.